ProQR Therapeutics (PRQR) Receivables - Other (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Receivables - Other for 13 consecutive years, with $361869.5 the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Other fell 81.57% year-over-year to $361869.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $361869.5 (down 81.57% YoY) and the FY2025 annual result came in at $356179.7, down 62.51% from the prior year.
• Receivables - Other improved to $361869.5 in Q1 2026 per PRQR's latest filing, from $356179.7 in the prior quarter.
• Over the last five years, Receivables - Other for PRQR reached as high as $4.6 million in Q2 2024 and fell as low as $356179.7 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.2 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other surged 98.67% — and 2026, when it tumbled 81.57%.
• Year by year, Receivables - Other stood at $426732.9 in 2022, then jumped by 98.67% to $847775.9 in 2023, then increased by 12.08% to $950191.8 in 2024, then tumbled by 62.51% to $356179.7 in 2025, then advanced by 1.6% to $361869.5 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $361869.5, $356179.7, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.